Viking Therapeutics
Yahoo Finance • 2 days ago
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Viking Therapeutics, Inc. (VKTX) closed at $36.75 in the latest trading session, marking a -11.76% move from the prior day. This change lagged the S&P 500's daily loss of 0.03%. At the same time, the Dow lost 0.31%, and the tech-heavy Nasd... Full story
Yahoo Finance • 2 days ago
Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes
* Viking Therapeutics (VKTX [https://seekingalpha.com/symbol/VKTX]) on Thursday announced the pricing of its concurrent public offerings of 7.85M shares of common stock, at a public offering price of $35.00 per share, and $225.0 million... Full story
Yahoo Finance • 2 days ago
At a glance: stocks gapping down premarket
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Thursday. Stock index futures were lower on Thursday after U.S. equities closed deep i... Full story
Yahoo Finance • 3 days ago
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Novo NVO announced two important regulatory updates in Europe late last week, putting its Rare Disease portfolio back in focus. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of d... Full story
Yahoo Finance • 3 days ago
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Shares of Viking Therapeutics VKTX rose about 36% on Tuesday after the company announced positive data from a maintenance dosing study evaluating its lead obesity candidate, VK2735. Results showed that participants preserved most of their... Full story
Yahoo Finance • 4 days ago
These ‘Moonshot’ Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts. Continue Reading... Full story
Yahoo Finance • 4 days ago
Lilly Rises Higher as Viking Preserves Up to 90% Monthly
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity-and-diabetes drug leader, confronted a fresh competitive wrinkle after Viking Therapeutics released maintenance-dosing results for VK2735. Lilly shares rise 0.8%... Full story
- LLY
Mentioned:
Yahoo Finance • 4 days ago
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Quick Read Viking Therapeutics surged 26% after VK2735 maintenance data validated monthly and every-other-week dosing schedules, directly addressing the adherence problem plaguing injectable GLP-1s. Obesity peers shrugged at the results,... Full story
Yahoo Finance • 4 days ago
Sandisk, Lennar, Viking Therapeutics, Shopify, GameStop, and More Stocks That Explain Today’s Market
Sandisk rises. Rosenblatt initiates coverage of the stock with a Buy rating and a price target of $2,400. Continue Reading... Full story
Yahoo Finance • 4 days ago
Top Midday Stories: Goldman Reportedly in Talks to Acquire $37 Billion Credit Firm Palmer Square; Viking Obesity Drug Candidate Showed 'Superior' Results in Study
The Nasdaq Composite was up, the Dow Jones Industrial Average was down, and the S&P 500 Index was ro PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 days ago
Alibaba Higher on Chip News; On Holdings Football Move | Stock Movers
On this episode of Stock Movers:- Alibaba (BABA) shares are higher this morning after the company rolled out what it calls China's most powerful AI chip and announced plans to expand data center capacity in the coming years.- ON Holdings (... Full story
Yahoo Finance • 4 days ago
Viking Therapeutics stock surges on promising weight-loss data: A closer look
Viking Therapeutics (VKTX) stock is surging after the company released trial data showing that its obesity drug resulted in 22% weight loss. Yahoo Finance Breaking Business News Reporter Jake Conley, Yahoo Finance Senior Autos Reporter Pr... Full story
Yahoo Finance • 4 days ago
Viking Therapeutics soars after trial data for obesity drug
[Orange And Blue Weight Scale Pills And Jabs On Blue And Orange Background] MicroStockHub Viking Therapeutics (VKTX [https://seekingalpha.com/symbol/VKTX]) added more than 30% in the premarket on Tuesday after disclosing that its GLP-1/GI... Full story
Yahoo Finance • 4 days ago
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell. Continue Reading... Full story
Yahoo Finance • 4 days ago
Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
Quick Read Citigroup's Geoff Meacham targets $1,600 for LLY, representing 37% upside, anchored by Mounjaro and Zepbound's combined $14.9B single-quarter revenue. Novo Nordisk dropped 8% in one session after its post-Wegovy update disappoi... Full story
Yahoo Finance • 8 days ago
4 Biotech Stocks to Watch as Potential Takeover Targets
M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain access to promising technologies and late-... Full story
Yahoo Finance • 9 days ago
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
Eli Lilly and Company's LLY stock has declined around 7.2% in the past month after gaining sharply earlier in 2026 and trading near record levels. At around 26.3x forward earnings, LLY continues to command a premium valuation, making the s... Full story
Yahoo Finance • 9 days ago
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
Novo NVO recently entered a new chapter by adopting "Novo" as its day-to-day name, as it seeks to sharpen its focus and competitiveness amid slowing growth and intensifying market competition. The move comes as the stock faces growing inve... Full story
Yahoo Finance • 12 days ago
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo NVO stock declined 2.1% on Friday as a Morgan Stanley downgrade added fresh pressure. The investment bank reportedly cut NVO to "Underweight" from "Equal-weight" while retaining a $40 (DKK 250) price target, arguing that the valuation... Full story
Yahoo Finance • 16 days ago
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Is it better to own a company already selling drugs or one with a potential blockbuster in testing? Investors are weighing Axsome Therapeutics (NASDAQ:AXSM) against Viking Therapeutics (NASDAQ:VKTX) to decide. Axsome focuses on commercial... Full story